Background-Observational studies and randomized, controlled trials have yielded uncertain results regarding the benefits of drug-eluting stents (DES) for the treatment of saphenous vein graft (SVG) disease. The objective of this meta-analysis was to assess the cumulative evidence regarding the efficacy and effectiveness of DES to treat SVG compared with bare metal stent (BMS). Methods and Results-We conducted a bayesian hierarchical meta-analysis of all randomized, controlled trials and observational studies that compared clinical outcomes after DES or BMS placement in SVG disease. Our search resulted in 25 studies, cumulating 5755 patients. DES implantation was not associated with an increased risk of death (odds ratio [OR], 0.85; 95% credible intervals (CrI) [CrI], 0.62 to 1.21) or myocardial infarction (OR, 0.83; 95% CrI, 0.56 to 1.32), but wide CrIs preclude definitive conclusions. Target vessel revascularization (OR, 0.55; 95% CrI, 0.39 to 0.76) and target lesion revascularization (OR, 0.58; 95% CrI, 0.37 to 0.87) were both reduced by approximately 45% with DES.
S aphenous vein graft (SVG) disease after coronary artery bypass surgery is common, with 50% of SVGs that develop significant stenoses and nearly 40% that are completely occluded 10 years after surgery. 1, 2 Recurrent angina occurs in up to 10% of patients per year as the result of graft failure or progression of disease in native vessels. 3 Percutaneous coronary intervention with bare metal stent (BMS) implantation has rapidly established itself as the treatment of choice to restore optimal flow and prevent graft failure, 4, 5 especially with regard to the high risk of repeating coronary artery bypass surgery in these patients. 6 Unfortunately, instent restenosis and reocclusion has always been particularly frequent (20% to 37%) when BMS are implanted in SVGs. 5, 7 Given that drug-eluting stents (DES) showed a clear benefit in reducing neointimal hyperplasia and in-stent restenosis in native coronary artery lesions, 8 -11 hope to translate such benefits to SVG disease has rapidly influenced clinical practice. However, in the DELAYED RRISC study, 12 a prospective, randomized trial of DES versus BMS in SVG lesions, the use of a sirolimus-eluting stent (SES), at a median follow-up of 32 months, was not associated with a reduction in repeat revascularization procedures. Furthermore, higher mortality was observed with SES implantation in this single trial. On the other hand, 1 randomized trial 13 and 12 observational studies 14 -25 have demonstrated improved outcomes with DES, and 8 studies suggested no difference between DES and BMS. 26 -33 Thus, the safety and efficacy of DES for off-label use in patients undergoing percutaneous coronary intervention for lesions in SVG remain uncertain and controversial. For that reason, we performed a meta-analysis, using bayesian statistical methods, to assess the cumulative evidence regarding the efficacy and effectiveness of DES to treat SVG compared with BMS.
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Methods
Search Strategy and Data Collection
We conducted a meta-analysis of observational and randomized trials comparing patients who underwent SVG percutaneous interventions with BMS or DES. For study selection, we searched through PubMed and the Cochrane Library, using the terms "saphenous vein graft" and "drug-eluting stent" (last update, June 30, 2010) . References of selected studies and recent international meetings programs were scrutinized for relevant unpublished data. To be included, the studies needed to report outcomes of both a DES and a BMS group for comparisons. When trials were reported in multiple forms, priority was given to the latest journal article. Two evaluators (M.P., S.R.) extracted all data independently, and discrepancies between datasets were resolved by consensus. The type of DES used and the duration of dual antiplatelet therapy with aspirin and a thienopyridine after the index percutaneous coronary intervention were noted in each trial. From each eligible study, we recorded information regarding the number of patients in each group and patient demographics. We recorded age of patients, prevalence of hypertension, diabetes, chronic renal insufficiency, mean left ventricular ejection fraction, and the mode of presentation (stable angina, unstable angina or non-ST-segment elevation-myocardial infarction [MI], ST-segment elevation MI). Furthermore, we extracted data on key procedural parameters such as age of the treated SVG, reference SVG diameter, lesion length, type of DES used, stent length, stent diameter, use of glycoprotein IIb/IIIa inhibitors, and use of embolic protection device. Finally, the following outcomes measures were extracted: death from any cause, MI (Q wave and non-Q wave), target vessel revascularization (TVR), target lesion revascularization (TLR), and stent thrombosis. We considered the longest available follow-up period for all events in each qualified study. TVR was most frequently defined as any repeated revascularization on the SVG treated, involving the treated segment or others segments. In most studies, TLR was defined as percutaneous or surgical revascularization secondary to a significant stenosis in the stent or within 5 mm from its proximal or distal margin. The standard definition of MI was a typical elevation of creatine kinase enzyme or troponin levels with either ischemic symptoms or ischemic ECG changes. For stent thrombosis, the criteria used in each individual eligible study were adopted.
Statistical Analysis
Bayesian hierarchical random-effects meta-analysis models were used for all outcomes. The probability of an event within each group from each trial was assumed to follow a binomial distribution. The binomial success parameters were allowed to vary between both DES and BMS groups within each study and between each study included in the meta-analysis. To model the between trial variability, the logarithms of the odds ratios (OR) of each outcome variable from each trial were assumed to follow a normal distribution. The mean of the normal distribution of log OR across trials, therefore, represents the average treatment effect in the trials, and the variance represents the variability of the treatment effect among trials. Throughout all analyses, low information prior distributions were used, so that the final inferences are based almost entirely on the observed data, and not on the information contained in the prior distributions. In particular, treatment means were normally distributed a priori with zero mean and variance of 1 million. Prior distributions for between-study variances were uniform on the range [0.001, 10], which is very wide on the log scale. Thus, the prior distributions were selected independently of any information contained in any of the studies.
To address concerns regarding the nonsignificant trend toward increased repeat revascularization procedures rates in the SES group after 6 months in the DELAYED RRISC trial (late catch-up phenomenon), 12 we also performed a subanalysis of TVR and major adverse cardiac events (MACE) as a function of available duration of follow-up.
All inferences were carried out using WinBUGS software (version 1.4, MRC Biostatistics Unit, Cambridge, United Kingdom). Win-BUGS programs are available from the authors on request. We ran 2 separate models, 1 for randomized trials and 1 for nonrandomized studies. Forest plots were produced to display the ORs and 95% credible intervals (CrI) for all major outcomes pooled in our meta-analysis. Credible intervals are the bayesian analog to frequentist confidence intervals.
Results
Study Selection and Characteristics
Our initial search yielded 106 items in PubMed, which were evaluated for eligibility. Of those, 83 were excluded based on their title or their abstract because (1) there was no BMS control group (nϭ5) or (2) their content was not directly related to our scientific objective (nϭ78). Of the 23 studies retrieved for more detailed evaluation, 1 article 34 was not considered in the data analysis because it pertained to an already selected study at a different follow-up time. Two other trials were obtained from the reference lists of retrieved articles. 26, 33 One study abstract was found after reviewing major meetings' programs. 35 Finally, 25 studies (22 observational, 14 -33,35,36 2 randomized, controlled trials, 12,13 and 1 secondary subgroup analysis of a randomized, controlled trial 37 ) were included in this study-level meta-analysis (Figure 1) . The main characteristics of the 25 studies are shown in Table 1 . Studies were published between 2005 and 2010. The majority of trials compared both SES and paclitaxel-eluting stents (PES) with BMS. In 1 trial, 28 SES, PES, and tacrolimuseluting stents were compared with BMS. Zotarolimus-eluting stents were used in a minority of patients (8%) in 1 study. 26 Five studies used SES exclusively, 12, 20, 22, 31, 33 whereas only 3 studies 13, 23, 32 reported outcomes with PES for the DES group. When specified, treatment with aspirin was quite homogenous in the studies. Most if not all patients were treated with lifelong aspirin (81 to 325 mg). Periprocedural treatment with clopidogrel was more disparate among eligible studies. In most trials, clopidogrel was prescribed for at least 1 month after BMS placement 13, [17] [18] [19] [21] [22] [23] 25, [27] [28] [29] 36 and for at least 3 18 -20,22,25,28 or 6 months 13, 14, 17, 19, 21, 23, 25, 27, 28, 32, 33, 36, 37 after DES implantation. In the DELAYED RISCC study, 12 clopidogrel was administered for at least 2 months in all patients. Follow-up ranged from 6 months 23,25 to 48 months, 18 for a weighted average follow-up of 22.3 months.
Patients, Demographics, and Procedural Characteristics
Demographic and procedural characteristics of the included patients are shown in Table 2 . A total of 5755 patients were included in our meta-analysis. When comparing demographic and procedural characteristics of DES (nϭ3016) versus BMS (nϭ2739) patients, age (69.5 years versus 69.0 years), prevalence of hypertension (76.0% versus 72.6%) or diabetes (35.8% versus 31.9%), mean left ventricular ejection fraction (48.6% versus 48.6%), age of the SVG (10.5 years versus 10.1 years), reference vessel diameter (3.18 mm versus 3.43 mm), stent diameter (3.21 mm versus 3.67 mm), lesion length (15.4 mm versus 14.9 mm), and stent length (25.1 mm versus 23.5 mm) were either similar or sometimes slightly worse in the DES group. The prevalence of chronic renal insufficiency in the DES group was twice that in the BMS group (18.5% versus 9.4%). However, acute coronary syndromes (59.8% versus 68.8%) were slightly more frequent in BMS patients and embolic protection (44.7% versus 40.3%) was less likely to be used, although rates were low in both groups.
Meta-Analysis of Studied Outcomes Measures
Forest plots of all analyses are presented in Figures 2 to 7. DES were associated with a 15% relative risk reduction in mortality (OR, 0.85; 95% CrI, 0.62 to 1.21) ( Figure 2 ), but with a wide credible interval that included numbers above the null value of ORϭ1. Similarly, use of DES was associated with a 17% relative risk reduction in MI (OR, 0.83; 95% CrI, 0.56 to 1.32) ( Figure 3 ), although again with a large credible interval precluding a definitive conclusion with the available data. DES implantation, however, was associated with an important reduction in TVR (OR, 0.55; 95% CrI, 0.39 to 0.76) ( Figure 4 ) and TLR (OR, 0.58; 95% CrI, 0.37 to 0.87) ( Figure 5 ). When combining these outcomes (death, MI, or TVR), DES were associated with a substantial 38% reduction in MACE (OR, 0.62; 95% CrI, 0.46 to 0.81) ( Figure 6 ). Stent thrombosis rates were available in only 15 studies. [12] [13] [14] [15] [17] [18] [19] 21, 22, 24, 25, 27, 30, 33, 36 Although the OR point estimate (OR, 0.54) suggests reduced risk for stent thrombosis with DES, the wide 95% CrI (0.13 to 1.39) precludes definitive conclusions regarding any benefit of DES over BMS (Figure 7 ) with regard to this specific end point.
In the subanalysis we performed to assess a potential late catch-up phenomenon, each study was classified in 1 of the 3 following categories: (1) follow-up Ͻ18 months, (2) follow-up between 18 to 30 months, and (3) follow-up Ͼ30 months. This additional analysis suggests consistent effect size and direction up to 30 months (Figure 8 ). However, beyond that point, the wide credible intervals preclude any strong conclusion on the persistence or disappearance of the effect.
Discussion
In our meta-analysis principally of observational studies, we demonstrated that DES are effective to reduce TVR and TLR in the treatment of SVG disease. However, despite cumulating the largest number of patients, the safety of DES implantation in SVG cannot be confirmed, given the large credible intervals observed for the point estimates of death, MI, and stent thrombosis. We can say, at most, that DES placement in an SVG is not associated with an important harm signal. Moreover, notwithstanding similar or slightly worse baseline characteristics in DES patients including higher prevalence of hypertension, diabetes, and chronic renal insufficiency, smaller reference vessel diameter or stent diameter, and less frequent use of gpIIbIIa inhibitors, there was a considerably positive impact, as expected with effective blockade of neointimal formation, on the reduction of TLR, TVR, and MACE. The effect of DES over BMS on the reduction of TVR and MACE appears consistent irrespective of the available duration of follow-up up to 30 months, mitigating a possible late catch-up phenomenon. However, beyond 30 months, our analysis could not rule out a disappearance of the clinical impact of DES over BMS on TVR or MACE because of large credible intervals. Also, although quite important, the 44% relative reduction in repeat revascularization procedures with DES in SVG remains smaller than the Ͼ70% observed in pivotal trials 8 -11 that randomly assigned patients with native coronary vessel stenoses.
Our meta-analysis is the latest and largest ever reported and the first to use bayesian statistical methods. Wöhrle et al 32 performed a meta-analysis that included only 280 patients in the DES group and 256 patients in the BMS group. In this study, risk of TVR (OR, 0.26; 95% confidence interval [CI], 0.16 to 0.44) and MACE (OR, 0.34; 95% CI, 0.21 to 0.54) were reduced with DES. In another quantitative synthesis of studies comparing DES and BMS in SVG, Brilakis et al 38 demonstrated an OR of 0.46 (95% CI, 0.31 to 0.66) for the incidence of MACE (death, MI, or ischemia-driven target SVG revascularization), in favor of DES. However, this analysis included only 711 patients. New studies have been published since these earlier works. Our results summarize data from all available studies comparing DES and BMS in SVGs, including the recent study by Latib et al published in this journal in 2010, 36 the contemporary data of the STENT registry, and the conflicting results of 2 randomized studies: the DELAYED RRISC 12 trial and the recently published SOS trial. 13 At a median follow-up of 1.5 years in the SOS trial, 13 mortality was similar in both PES and BMS groups (hazard ratio [HR], 1.56; 95% CI, 0.72 to 4.11), although numerically favoring the BMS group. In contrast, in the randomized RRISC study, 34 after a median follow-up of 32 months, not only the rate of TVR was similar in the DES and BMS groups, caused by a late catch-up phenomenon in the SES group, but mortality was higher in DES patients (29% versus 0%; absolute risk difference of 29%; 95% CI, 14% to 45%, PϽ0.001). Clopidogrel was mandated for only 2 months in this trial. Considering data showing that prolonged dual antiplatelet therapy may prevent death or MI in individuals receiving DES, 39 this short dual antiplatelet treatment might account for the increased late mortality. Although an ␣ error or a deleterious "chance" effect could also have affected the results of this small, randomized trial, it initially certainly raised concerns about the use of SES in SVG atherosclerotic lesions. SES and PES differ significantly in their structural stent design, impregnated polymer, type of drug, and pharmacokinetic profile. Those differences may have a paramount influence on the distinctive clinical and angiographic outcomes after DES implantation in SVG disease noted in these 2 published randomized studies. Whether DES exerts a class effect in SVG remains to be confirmed. The recently published VELETI pilot trial 40 results comparing PES placement in nonsignificant SVG stenosis versus medical therapy further reinforce the huge potential impact of PES to halt disease progression and prevent graft failure, as in the SOS trial. In the era of prolonged (Ն1 year) dual antiplatelet therapy, DES may be the stents of choice for the treatment of significant SVG disease, although safety data are definitely needed. The results of this study, as for all study-level meta-analysis, should be interpreted with caution. As it is the case in virtually every meta-analysis, despite all our efforts to mitigate this limitation, it is worth mentioning that there is a possibility of publication or selection bias. Even with 25 studies, the available sample size remains relatively small. This leads to large credible intervals for death, MI, and stent thrombosis and precludes more refined subgroups analyses. Note that our model does not assume homogeneity between studies, because our random-effects model specifically estimates between study variance, and accounts for this in the summary credible intervals reported. In addition, the between-study heterogeneity is clearly displayed in each forest plot. The disparity in study designs, dual antiplatelet treatment duration, follow-up, and the rates of follow-up angiography could have contributed to some of the betweenstudy variability. By promoting higher percentages of coro-nary revascularization in the BMS patients, who have higher late loss and angiographic restenosis, studies with mandated angiographic follow-up were more susceptible to show an advantage for DES in SVG. In fact, mandatory follow-up angiography in some studies may have accentuated differences in revascularization rates beyond those which might have been expected with routine clinical care. Also, the majority of BMS used in SVG studies had a thick strut design. Because thicker-strut stents induce more restenosis compared with thinner-strut stents, 41 the difference in TVR and TLR between DES and thick-strut BMS may be significantly larger than the difference between DES and more recent thinner-strut BMS. Also, there are no published trials or observational studies with the new-generation DES (everolimus-eluting or zotarolimus-eluting stents). Therefore, the results of this meta-analysis should not be generalized to these newer DES platforms. Finally, most studies were nonrandomized observational trials. Therefore, the current meta-analysis is subject to inherent limitations, particularly hidden biases caused by unmeasured confounders. However, we tried to capture many variables that could potentially confound this analysis ( Table 2) , finding that groups were relatively well balanced at baseline. Moreover, we believe it is unlikely that unmeasured confounders could negate all the observed benefits with DES.
In conclusion, acknowledging the caveats, our bayesian meta-analysis cumulating data from 5755 patients indicates that the use of DES, as for the treatment of native coronary disease, is highly effective to reduce TVR and TLR, when implanted in SVGs. We found no strong evidence for a difference in mortality, MI, or stent thrombosis with DES use compared with BMS, but wide credible intervals preclude a definitive conclusion. Our results thus indicate that further data are needed. A large, adequately powered, multicenter, randomized, controlled trial with a long enough follow-up period could definitely help to answer whether DES implantation, especially newer-generation platforms, is safe compared with thinner-strut BMS in SVG atherosclerotic lesions.
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